Literature DB >> 11016912

Validation of a screening questionnaire for androgen deficiency in aging males.

J E Morley1, E Charlton, P Patrick, F E Kaiser, P Cadeau, D McCready, H M Perry.   

Abstract

It is now well established that testosterone levels decline with age. What has not been established is whether the decline in testosterone is associated with a symptom complex. This study examined whether certain symptoms are more commonly present in males with low bioavailable testosterone (BT) levels. These were used to evaluate a questionnaire for androgen deficiency in aging males (ADAM). The validity of the ADAM questionnaire to screen for low BT was tested in 316 Canadian physicians aged 40 to 62 years. Low BT levels were present in 25% of this population. None had elevated luteinizing hormone (LH) levels. The ADAM questionnaire had 88% sensitivity and 60% specificity. When the questionnaire was administered twice 2 to 4 weeks apart to 10 men, it was determined that the coefficient of variation was 11.5%. In a second study of 34 ADAM-positive patients, 37% of those with clearly normal BT levels demonstrated some evidence of dysphoria. Finally, in 21 patients who were treated with testosterone, improvement on the ADAM questionnaire was demonstrated in 18 (P = .002). These data support the concept of a symptom complex associated with low BT levels in aging males. In addition, the ADAM questionnaire appears to be a reasonable screening questionnaire to detect androgen deficiency in males over 40 years of age.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016912     DOI: 10.1053/meta.2000.8625

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  92 in total

Review 1.  Osteoporosis in men: are we ready to diagnose and treat?

Authors:  H M Perry; J E Morley
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 2.  [Symptoms or complaints in the aging male--which questionnaires are available?].

Authors:  M E Beutel; H Schneider; W Weidner
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

Review 3.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 4.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

5.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

Review 6.  How to recognize late-onset hypogonadism in men with sexual dysfunction.

Authors:  Giovanni Corona; Giulia Rastrelli; Linda Vignozzi; Edoardo Mannucci; Mario Maggi
Journal:  Asian J Androl       Date:  2012-01-30       Impact factor: 3.285

7.  Serum total testosterone level and identification of late-onset hypogonadism: a community-based study.

Authors:  Sungmin Kang; Hyun Jun Park; Nam Cheol Park
Journal:  Korean J Urol       Date:  2013-09-10

8.  The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission.

Authors:  Thomas G Travison; Rebecca Shackelton; Andre B Araujo; Susan A Hall; Rachel E Williams; Richard V Clark; Amy B O'Donnell; John B McKinlay
Journal:  J Am Geriatr Soc       Date:  2008-05       Impact factor: 5.562

9.  Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Authors:  Andrew J Weickhardt; Robert C Doebele; W Thomas Purcell; Paul A Bunn; Ana B Oton; Micol S Rothman; Margaret E Wierman; Tony Mok; Sanjay Popat; Julie Bauman; Jorge Nieva; Silvia Novello; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

Review 10.  Reproductive health in the adolescent and young adult cancer patient: an innovative training program for oncology nurses.

Authors:  Susan T Vadaparampil; Nicole M Hutchins; Gwendolyn P Quinn
Journal:  J Cancer Educ       Date:  2013-03       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.